Neurobehavioral impairments from chromium exposure: Insights from a zebrafish model and drug validation.

Autor: Boopathi S; Toxicology and Pharmacology Laboratory, Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India. Electronic address: https://twitter.com/@iamboopathi., Haridevamuthu B; Toxicology and Pharmacology Laboratory, Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India., Gandhi A; Toxicology and Pharmacology Laboratory, Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India., Nayak SPRR; Toxicology and Pharmacology Laboratory, Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India., Sudhakaran G; Toxicology and Pharmacology Laboratory, Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India., Rajagopal R; Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia., Arokiyaraj S; Department of Food Science & Biotechnology, Sejong University, Seoul 05006, Republic of Korea., Arockiaraj J; Toxicology and Pharmacology Laboratory, Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India. Electronic address: jesuaroa@srmist.edu.in.
Jazyk: angličtina
Zdroj: Comparative biochemistry and physiology. Toxicology & pharmacology : CBP [Comp Biochem Physiol C Toxicol Pharmacol] 2024 Jan; Vol. 275, pp. 109780. Date of Electronic Publication: 2023 Oct 25.
DOI: 10.1016/j.cbpc.2023.109780
Abstrakt: We have developed a zebrafish model to explore the alterations in neurobehaviors resulting from both acute and chronic exposure to chromium (Cr). Zebrafish exposed to half (HC group: 19.7 mg/L) and a quarter (LC group: 9.85 mg/L) of the LD50 concentration of Cr for a span of 2 weeks exhibited aberrant locomotion, heightened anxiety, cognitive impairment, and reduced aggression - hallmark traits reminiscent of an Alzheimer's Disease (AD)-like syndrome. Furthermore, zebrafish exposed to an environmentally relevant concentration of Cr (EC group: 100 μg/L) for an extended period of 9 weeks exhibited behaviors comparable to those observed in the HC group. Moreover, the study investigated the neuroprotective effects of donepezil (Don), galantamine (Gal) and resveratrol (Res) drugs in response to neurobehavioral impairments induced by Cr (VI) exposure in zebrafish. Don and Res effectively protect the zebrafish from Cr (VI)-induced anxiety, and memory impairment. Furthermore, Cr (VI) exposure induced heightened oxidative stress while simultaneously diminishing antioxidant enzyme levels. Remarkably, these effects were counteracted in the drug-treated groups. Likewise, exposure to Cr (VI) led to an increase in the expression of genes linked to AD and neuroinflammation. Nevertheless, drug treatment reversed this effect in Cr (VI)-exposed fish. The results of our study highlight the potentials of zebrafish model in demonstrating neurobehavioral impairments induced by Cr (VI), thereby paving the way for its utilization in vivo neurobehaviors investigations and pharmaceutical screening.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: